Bonus Episode: Psychedelic Research Inside an Academic Medical Center with Scott Thompson, PhD
In this bonus episode, Dr. Ben Everett speaks with Scott Thompson, PhD, professor of psychiatry at the University of Colorado School of Medicine, where he directs the Novel Therapeutics in the Brain and Behavior Innovation Center and leads the Psychedelic Public Policy Partnership. Drawing on more than 40 years of synaptic research, Dr. Thompson describes how an unexpected finding on SSRI action led his lab to show in mice that psilocybin's antidepressant-like effects persisted even when the 5-HT2A receptor was blocked, and what that finding means for the question of whether the psychedelic experience itself is the medicine.As psychedelic compounds advance through late-stage development, clinicians face open questions about mechanism, trial design, safety, and access. This conversation covers functional unblinding and the search for objective endpoints such as anhedonia, what it takes to run Schedule I research inside an academic medical center, and real-world outcome and safety data from more than 2,300 people who received regulated psilocybin services in Colorado and Oregon. Dr. Thompson also discusses the role of psychotherapy, the evidence on microdosing, and phase III programs including Definium's DT120 LSD formulation and Beckley Atai's intranasal 5-MeO-DMT.KEY EPISODE HIGHLIGHTS: A SUPERCHARGED SSRI [45:30]“psychedelics do what SSRIs do. They just do it more potently and more quickly.”Dr. Thompson's working hypothesis frames psychedelics as faster, stronger versions of a mechanism clinicians already use every day, which shapes how his lab tests whether the trip is required.A DOSE CEILING IN REAL-WORLD DATA [27:31]“people who got doses of psilocybin less than thirty milligrams displayed the same improvement in symptoms as people who got doses more than thirty-five”Outcome data from more than 2,300 regulated psilocybin clients suggest a threshold rather than a linear dose-response, challenging the assumption that higher doses yield greater benefit.MICRODOSING AND EXPECTANCY [31:00]“There's strong evidence now that microdosing is primarily a placebo effect.”Placebo-controlled studies show benefit tracks what participants believed they received rather than what they actually took, useful context when patients ask about microdosing.CHAPTERS:00:00 – Introduction: Is the Experience the Medicine?02:00 – From Basel and Zurich to Psilocybin and Synaptic Plasticity07:30 – Psychedelic Research and Policy at CU Anschutz10:30 – Functional Unblinding and the Search for Objective Endpoints15:00 – Facilitator Support, Placebo Response, and Predictive Biomarkers20:00 – Building Safety Into Colorado's Regulated Psilocybin Services24:30 – Real-World Outcomes From Colorado and Oregon Psilocybin Clients28:00 – Dose Thresholds, MEQ-30 Scores, and the Evidence on Microdosing32:00 – Running Schedule I Research: Regulation, Funding, and INDs36:30 – Safety Signals: Psychosis, Suicidality, and Adverse Event Follow-Up43:00 – Blocking the 5-HT2A Receptor: Is the Trip Necessary?47:30 – Cost, Access, and Shorter-Acting Psychedelics50:30 – Receptor Promiscuity and Non-Hallucinogenic Compounds53:30 – The Role of Psychotherapy in Psychedelic Treatment59:30 – Definium's DT120: Phase III Data, Payer Realities, and Dose Selection01:07:00 – Beckley Atai's 5-MeO-DMT and Other Short-Acting Compounds01:09:30 – Clinical TakeawaysLINKS:Full transcript and show notes:https://www.psychiatrist.com/jcp/ep27-psychedelic-research-academic-medical-center-scott-thompson/Journal of Clinical Psychiatryhttps://www.psychiatrist.com/jcp/Publisher of peer-reviewed research discussed in this episode.Dr. Scott Thompson – LinkedInhttps://www.linkedin.com/in/scott-thompson-241a1a15/Harnessing Psilocybin (Hesselgrave et al., PNAS, 2021)https://doi.org/10.1073/pnas.2022489118Dr. Thompson's mouse study showing psilocybin's antidepressant-like effects persisted despite 5-HT2A receptor blockade.Colorado Natural Medicine Programhttps://dpo.colorado.gov/NaturalMedicineState program for regulated psilocybin services discussed in this episode.Definium Therapeuticshttps://definiumtx.comDeveloper of DT120, the LSD formulation with phase III results in MDD and GAD.#Psilocybin #PsychedelicMedicine #LSD #Neuroplasticity #FunctionalUnblinding